Key result
Expert interviews highlighted the advent of targeted therapies like cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy and identified non-obstructive disease as a significant unmet need.
Expert perspectives emphasize the transformative potential of cardiac myosin inhibitors and precision medicine in managing hypertrophic cardiomyopathy, while noting non-obstructive disease remains an unmet need.
Hypertrophic cardiomyopathy (HCM) is an inherited disorder that may cause disabling and potentially life-threatening symptoms related to thickening of the left ventricular wall. The impact of pathophysiological research on the treatment of HCM was central to the discussions with Gerald Carr-White, Deputy Medical Director of the Cardiovascular, Respiratory and Critical Care Unit at Guy’s and St Thomas’ NHS Foundation Trust, London, UK; and Michelle Michels, Head of the Center of Expertise for Inherited Cardiovascular Disease at the Erasmus University Medical Centre, Rotterdam, the Netherlands, during interviews conducted for the European Medical Journal (EMJ) in May and August 2024. The experts provided an overview of current options for the symptomatic treatment of HCM, including the advent of targeted therapies, cardiac myosin inhibitors (CMI), for the obstructive form of the condition. They explored the advantages and limitations of current therapies and shared their informed opinions on how precision medicine and genetic therapies have the potential to transform patient care. While highlighting the treatment of non-obstructive disease as a significant unmet need, Carr-White and Michels expressed optimism for the future of HCM treatment, driven by an understanding of the underlying pathophysiology and guided by increasing clinical and real-world evidence.
No takes yet. Share an insight, caveat, or question.
Juliet George (2024) conducted a review in Hypertrophic cardiomyopathy (HCM). Cardiac myosin inhibitors (CMI) was evaluated. Expert interviews highlighted the advent of targeted therapies like cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy and identified non-obstructive disease as a significant unmet need.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: